Microbix Biosystems Inc., a life science company, manufactures viral and bacterial antigens and reagents for the diagnostics industry worldwide. The company produces infectious disease antigens, including viral, bacterial, and parasitic products, which are used in various applications, such as immunodiagnostic assays comprising ELISA, chemiluminescent automated immunoassays, immunohistochemistry, immunofluorescence, latex agglutination, rapid tests, and flow cytometry. Its infectious disease antigens also used in controls for diagnostic assays, basic and applied research in virology, microbiology, cell biology, immunology, and pathology, or for vaccine and antiviral research and development. The company also provides quality assessment products, including PROCEEDx Verification/Validation samples, which are research use only products for use in test system IQ/OQ/PQ, verification/validation, and training; PTDx proficiency testing products; and REDx Controls, which are designed to enhance the diagnostic quality outcome by early detection of the deviations from desired assay performance. In addition, it develops Kinlytic Urokinase for injection, a thrombolytic biologic drug used to treat blood clots; and LumiSort cell-sorting, a technology for sorting of particles that could be used to enrich cell populations of interest, such as in sexing semen. The company also offers viral transport media that stabilize the organisms in patient samples. Microbix Biosystems Inc. was founded in 1988 and is based in Mississauga, Canada.

This security is traded over-the-counter, or OTC. We don't always have accurate pricing data on OTC stocks.

$0.59    OTCQX
As of 01/14/2022     OTCMarkets

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Index country:  Canada
Country of incorporation:  
IPO date:  12/07/2018
Outstanding shares:  131,087,086
Average volume:  5,641
Market cap:   $76,043,619
Current dividend yield:  0.00%
Valuation   (See tab for details)
PE ratio:   -30.38
PB ratio:   4.10
PS ratio:   4.85
Return on equity:   -15.13%
Net income %:   -16.14%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy